iRECIST Criteria for Evaluation of the Response of Immunotherapy in Solid Tumors

The Response Evaluation Criteria in Solid Tumors (RECIST1.
1) is based on the change in tumor size to evaluate the efficacy, which is also the current gold standard for evaluating the efficacy of tumor treatment
.

defect:

The Response Evaluation Criteria in Solid Tumors (RECIST1.

①To determine the overall treatment effect of the disease by reflecting the local curative effect with a single imaging data;

②The tumor shrinkage for 4 weeks only reflects the short-term curative effect;

②The tumor shrinkage for 4 weeks only reflects the short-term curative effect;

(3) Using a single objective standard to reflect complex lesions, ignoring changes in tumor burden, which often best reflects the quality of life and survival time of patients
.

(3) Using a single objective standard to reflect complex lesions, ignoring changes in tumor burden, which often best reflects the quality of life and survival time of patients
.

To evaluate the efficacy of tumor immunotherapy according to the traditional efficacy evaluation system, it is often concluded that the treatment is ineffective because there is no obvious tumor change, and the traditional efficacy evaluation system is not enough to capture false progress, which may underestimate immune checkpoints The therapeutic benefit of blocking
.

To evaluate the efficacy of tumor immunotherapy according to the traditional efficacy evaluation system, it is often concluded that the treatment is ineffective because there is no obvious tumor change, and the traditional efficacy evaluation system is not enough to capture false progress, which may underestimate immune checkpoints The therapeutic benefit of blocking
.

iRECIST Criteria iRECIST Criteria

(1) Compared with the RECIST1.
1 standard, the principles of tumor efficacy evaluation and lesion measurement methods have not changed much.
The main change of iRECIST is to define the delayed effect of tumor immunotherapy, that is, those who have been assessed as progressing according to the RE-CIST1.
1 standard.
The patient developed disease control after continuing immunotherapy
.

(2) iRECIST adds the concept of iUPD on the basis of RECIST1.

"Clinically stable" definition: an increase in per-formance status (PS) score; no increase in disease-related clinical symptoms, such as pain, dyspnea, appetite, weight loss, and the patient's own feelings; no increase in disease-related symptoms Treatment of symptoms, such as pain relief, radiation therapy, or other palliative care
.

"Clinically stable" definition: an increase in per-formance status (PS) score; no increase in disease-related clinical symptoms, such as pain, dyspnea, appetite, weight loss, and the patient's own feelings; no increase in disease-related symptoms Treatment of symptoms, such as pain relief, radiation therapy, or other palliative care
.

"Clinically stable" definition: "Clinically stable" definition:Increased per-formance status (PS) score; no worsening of disease-related clinical symptoms such as pain, dyspnea, loss of appetite, weight, and patient's own feeling, etc.

 

Note: This article is from the Internet, and the content has increased or decreased
.

The editor has reviewed the content

Remarks: Remarks: This article is sourced from the Internet, and the content has increased or decreased

References References

[1] Jiang Qionghui, Lu Zejun, Yang Ping.
Evaluation Criteria for Tumor Immunotherapy Efficacy: Interpretation of iRECIST [J].
Journal of Translational Medicine, 2020, 9(1): 57-60.

[2] Seymour L, Bogaerts J, Perrone A, et al.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lancet Oncol.
2017 Mar;18(3):e143-e152.
doi: 10.
1016/S1470-2045 (17) 30074-8.
 

WeChat scan and
follow the public account

: ,
.

video Applets great , double-tap to unlike look in , double-tap to cancel watching

:,
.
videoAppletsgreat, double-tap to unlikelook in, double-tap to cancel watchingleave a message here